Intervista a Sandro Bandini

Liu S. , Tang W. , ZHO U. . Fibroblastic growth factor 23 is counter-regolatory Phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305–15.

Silver S. , Naveh-Many T. Phosphate and the parathyroid. Kidney Int 2009; 75: 898–905.

Nabeshima Y. , Imura H. αKlotho: A regulator that integrates calcium homeostasis. Am J Nephrol 2008; 28: 455–64.

Krajisnik T. , Bjorklund P. , Marsell R. . Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125–31.

Ben-Dov I.Z. , Galitzer H. , Lavi-Moshayoff V. . The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117(12): 4003–8.

Gutierrez O.M. Fibrobastic Growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the “Trade Off” hypothesis”. Clin J Am Soc Nephrol 2010; 5(9): 1710–6.

Ix J.H. Fibroblastic growth factor and early decrements of renal function: the heart and soul study. Nephrol Dial Transplant 2010; 25(3): 993–7.

Evenepoel P. , Meijers B. , Viaene L. . Fibroblastic growth factor-23 in early chronic kidney disease; additional support in favour of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5(7): 1268–76.

Oliveira R.B. , Cancela Al , Graciolli F.G. . Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286–91.

Pereira R.C. , Juppner H. , Azucena-Serrano C.E. . Pat-terns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161–68.

Komaba H. , Goto S. , Fujii H. . Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands for uremic patients. Kidney Int 2010; 77(3): 232–8.

Kumata C. , Mizobuchi M. , Ogata H. . Involvement of alpha-Klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 2010; 31(3): 230–8.

Canalejo R. , Canalejo A. , Martinez-Moreno J.M. . FGF23 fails to inhibit parathyroid glands. J Am Soc Nephrol 2010; 21: 1125–35.

Galitzer H. , Ben-Dov I.Z. , Silver J. . Parathyroid cell resistance to fibroblstic growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77(3): 211–8.

Isakova T. , Gutierrez O.M. , Smith K. . Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2010; Jul 14 (Epub ahead of print).

Gonzales E.A. , Sachdeva A. , Oliver D.A. . Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503–10.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 113(Suppl), S1–130.

Coen G. , Mantella D. , Manni M. . 25-hydroxyvitamin leves and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68: 1840–8.

Autier P. , Gandini S. Vitamin D supplementation and total mortality. Arch Intern Med 2007; 167: 1730–37.

Kooienga L. , Fried L. , Scragg R. . The effect of combined calcium and Vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53(3): 408–16.

Coyne D. , Acharya M. , Qiu P. . Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4. Am J Kidney Dis 2006; 47: 263–76.

Levin A. , Bakris G.L. , Molitch . Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–8.

Agarwal R. , Acharya M. , Tuian J. . Antiproteinuric effect of paracalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–38.

Slatopolsky E. , Cozzolino M. , Finch J.L. Differential effect of 19-Nor-1,25–(OH)2D2 and lalpha-hydroxyvitamin D2, on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62(4): 1277–84.

Souberbille J.L.P. , Roth H. , Fougere D.P. . Parathyroid hormone measurement in CKD. Kidney Int 2010; 77: 93–100.

Marangella M. PTH a che punto siamo con il dosaggio? Giornale Italiano di Nefrologia, 2009; 5: 600–7.

Messa P. , Macario F. , Yaqoob M. . The OPTIMA study: assessing a new Cinacalcet treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45.

Fishbane S. , Shapiro W.B. , Corry D.B. . Cinacalcet HCL and concurrent low dose of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism in dialysis patients comparing with vitamin D alone. The ACHIEVE Study results. Clin J Am Soc Nephrol 2008; 3: 1718–25.

Urena P. , Jacobson S.H. , Zitt E. . Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real world clinical opractice- The ECHO observational study. Nephrol Dial Transplant 2009; 24(9): 2852–9.

Floege J. , Raggi P. , BlocK G.A. . Study design and subject baseline characteristics in the ADVANCE Study: effects of Cinacalcet on vascular calcification in hemodialysis patients. Nephrol Dial Transplant 2010; 1–8.